A Korean biotech company is looking for innovative biological technologies in early research stage with mechanism of action (MOA) and efficacy test results to perform further development of non-clinical studies and clinical trials for commercialization

Summary

A Korean company has proven experience in the development of biopharmaceutical products based on technology transfer from a foreign company. The company is looking for companies, research institutions, or universities in EU countries that have innovative technologies targeting mitochondria metabolism, autophagy, or micropinocytosis in KRAS (Kirsten RAt Sarcoma) mutant or wild-type cancer cells under a license agreement or a research cooperation agreement.

Description

The Korean company is looking for innovative technologies targeting mitochondria metabolism, autophagy, or micropinocytosis in KRAS* mutant or wild-type cancer cells.

The company has long-standing experts with extensive experience for more than 30 years so that drug development and commercialization can be implemented without difficulty. The team’s core competency is the ability to perform at a high-quality level in specific consulting projects for decades such as IND (Investigational New Drug), clinical trials, marketing approvals in home and abroad, protein/antibody therapeutics, cell/gene therapy, vaccines, etc.

One area of mediate interest is the high basal autophagic flux and autophagosome-lysosome fusion pathway under the hypoxic and/or nutrients-depleted environment of cancer cells. Autophagy defect often results in cancer cell death due to lysosome inhibition to impair autophagosome-lysosome fusion.

The company wants to in-license the technology and/or material for further development and commercialization under a license agreement. As for inflammation diseases, the company is looking for a partner(s) to do joint research with provided test materials provided under a research cooperation. Target diseases are open to discussion, but the company prefers a specific area with lots of research papers and data of partners'.

The company intends to perform further development of non-clinical studies and clinical trials for commercialization after the technology transfer from the European entities.

*KRAS operates an 'on-off system' that regulates GDP( Guanosine diphosphate)deactivation or GTP(Guanosine-5'-triphosphate) activation. This signals cell growth by alternating between GTP active and GDP inactive.

Technical Specification or Expertise Sought

Technical Specification Sought: Partners are expected to help develop products for inflammation diseases and cancers without chemicals. Peptides, proteins, or antibodies are acceptable. The manufacturing process and productivity do not matter.

Stage of development

Under development/lab tested

Contact/ source: Enterprise Europe Network (europa.eu)